REVIEW

Temozolomide and oral etoposide in children with recurrent malignant brain tumors

Antonio Ruggiero MD, Anna Ariano MD, Silvia Triarico MD, Michele Antonio Capozza MD, Alberto Romano MD, Palma Maurizi MD, Stefano Mastrangelo MD, Giorgio Attinà MD

Pediatric Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica Sacro Cuore, Rome, Italy

Abstract

Despite advances in the treatment of brain tumors, the prognosis of children with recurrent malignant brain tumors remains poor. Etoposide (VP-16), an inhibitor of nuclear enzyme deoxyribonucleic acid (DNA)-topoisomerase II, has shown activity in brain tumors. Its efficacy appears schedule dependent but, to date, the most effective schedule of administration has not been well defined. Temozolomide (TMZ), like VP-16, penetrates the blood–brain barrier and has activity against malignant brain tumors. This novel alkylating agent is rapidly absorbed and is highly bioavailable after oral administration. The antitumor activity of TMZ has been shown to be schedule dependent. Based on the evidence of different mechanisms of cytotoxicity, TMZ and VP-16 have been utilized in combination in patients with malignant brain tumors. This review evaluates the results derived from the combination use of TMZ and oral VP-16. The reported data suggest potential activity of oral VP-16 and TMZ alone or in combination. Further clinical trials are needed to explore and confirm their promising activity in relapsed brain neoplasms.

Keywords: etoposide, glioma, medulloblastoma, recurrent brain tumor, temozolomide.

Citation

Ruggiero A, Ariano A, Triarico S, Capozza MA, Romano A, Maurizi P, Mastrangelo S, Attinà G. Temozolomide and oral etoposide in children with recurrent malignant brain tumors. Drugs in Context 2020; 9: 2020-3-1. DOI: 10.7573/dic.2020-3-1

Introduction

Based on the 2016 World Health Organization’s classification of tumors of the central nervous system (CNS), glial tumors or gliomas include astrocytomas, glioblastomas, diffuse midline gliomas, oligodendrogliomas, mixed tumors, or oligoastrocytomas.1

Glioblastoma multiforme and anaplastic astrocytoma constitute 15–20% of all pediatric CNS tumors and represent a therapeutic challenge for clinicians due to their resistance to curative treatment. The supratentorial hemispheres or the brainstem area are commonly involved by these malignant tumors. A multimodality approach, including neurosurgery, radiotherapy (RT), and chemotherapy (CT), is the common treatment reserved for children affected by supratentorial astrocytomas and aged more than 3 years.

Despite the adoption of a multimodality approach, the long-term outcome of patients affected by these tumors is still grim. Two-year survival rate is less than 30% for supratentorial tumors and less than 10% for most pontine gliomas.2

It should be noted that the therapeutic approach of children with high-grade glioma depends on the peculiar characteristics of these tumors at this specific age, first of all somatic histone mutations.

For example, a specific group of tumors, primarily occurring in children, is characterized by K27M mutations in the histone H3 gene $H3F3A$, or less commonly in the related $HIST1H3B$ gene, encoding for histone 3 variants H3.3 and H3.1, respectively, which are considered hallmark events driving gliomagenesis. A further case is represented by the methylation of the MGMT gene promoter: MGMT promoter-methylated tumors appear to have a better response to alkylating agents when compared to MGMT promoter-unmethylated tumors. Mutations of the isocitrate dehydrogenase gene and tumor suppressor gene $TP53$ represent novel indicators for the clinical outcome of children with malignant glioma by influencing their poor responsiveness to temozolomide (TMZ).3,4

The treatment of patients with malignant brain tumors remains challenging. The aim of our manuscript is to review the results derived from the combination use of TMZ and oral VP-16. For this purpose, we conducted a literature research of the MEDLINE PubMed database on articles published between 1980 and 2019 reviewing: “Temozolomide AND oral etoposide AND central nervous system tumor(u)r.”
CNS tumors and treatment

The overall survival (OS) for patients with recurrent or progressive high-grade gliomas is extremely poor, with more than 80% of affected children dying within 24 months from diagnosis. The treatment is based at first on maximal safe surgical resection. Surgery is generally associated with RT in children with an age more than 3 years, whereas for young children aged less than 3 years, RT is postponed in order to preserve the developing brain from severe RT-related late effects. The role of adjuvant CT is unclear; so, whenever available, children can be enrolled in clinical trials with new antineoplastic agents. Wong and colleagues in their meta-analysis on the role of prognostic factors in recurrent gliomas reported an objective (complete response [CR] plus partial response [PRI]) response rate of 9%, with a median progression-free survival (PFS) and a median OS of 10 and 30 weeks, respectively, from relapse. In recurrent childhood gliomas, Huncharek and colleagues reported a systematic analysis of 27 nonrandomized clinical trials; a median overall response rate of about 14% and a time to progression from 29.4 to 49.7 weeks were found. Tumors recurring locally, if feasible, can be approached with a complete re-excision. Conventional RT still remains a treatment modality for children who have not previously received RT. Stereotactic radiation therapy has been adopted in adults with high-grade gliomas, but its real role in achieving a local control in children with brain tumors is still unclear. Radiosurgery, by delivering high dose-per-fraction treatments to small intracranial lesions, can play a key role in the treatment of unresectable, residual, or recurrent tumors previously treated with RT. Unfortunately, the efficacy of antineoplastic compounds in patients with recurrent disease is negligible. Many phase II clinical trials adopting multiple new antineoplastic agents showed a marginal clinical benefit for this setting of patients. Medulloblastoma (MB) is the most common malignant brain tumor. Standard treatment consists of surgery aimed to excise as much tumor as possible followed, except for young children aged less than 3 years, by whole neuraxis RT. MB is clearly a chemosensitive tumor with several phase II studies showing chemotherapeutic activity in relapsed tumor, but the vulnerability of the immature CNS of that population to neurotoxic therapy can negatively impact on treatment. Children with MB are generally stratified into “standard risk” and “high risk” categories based on the presence of metastases and volume of postoperative tumor. In average-risk patients older than 3 years, the treatment involves surgery and adjuvant RT followed by CT. In high-risk patients older than 3 years, the treatment involves surgery, RT with concomitant CT, followed by CT. Whereas, in infants and children less than 3 years of age, the treatment includes surgery and CT. The benefit of pre- and/or post-CT in nonmetastatic MB is accepted by several international groups. However, this benefit in terms of improving survival is yet to be fully established in terms of results from randomized clinical trials. Likewise, in metastatic MB, the addition of CT to RT seems to increase the survival rate. Although many children treated for MB can have long survival, 30–50% of them will relapse with an almost inevitably fatal disease. Children with relapsed MB carry a poor prognosis, especially when the relapse occurs after conventional RT, and only few long-term survivors are reported following additional treatments, including surgery, RT, and CT. The few reports on long-term survivors with recurrent MB have a median survival less than 1 year. Data from the Children’s Hospital of Philadelphia on 23 children with recurrent MB showed a poor outcome: the median survival was 5 months and the longest survivor was 28 months from relapse.

Similar data were registered in patients by the Stanford University Medical Center: no long-term survivors with relapsed MB were noted. Finally, among 46 children with recurrent MB treated according to Société Française d’Oncologie Pédiatrique (SFOP) protocols M7, MB, or M9, only one was cured and alive.

Etoposide

Etoposide (VP-16), an inhibitor of the catalytic cycle of deoxyribonucleic acid (DNA)-topoisomerase II, is an antineoplastic agent adopted for the treatment of multiple brain tumors. Its efficacy appears schedule dependent but, to date, the most effective schedule of administration has not been well defined. The optimum route of administration and dosing schedule for VP16 have been exhaustively investigated. Infusional (intravenous and intra-arterial), oral, and even intrathecal administrations have been compared in the treatment of advanced malignancies, including breast, lung, ovarian, and soft tissue sarcoma as both a first-line and salvage regimen. Data from pharmacological studies have shown that a prolonged administration schedule of VP-16 can enhance the cytotoxic activity of the drug and, similar to the intravenous administration, the oral dosing is able to achieve the equivalent cytotoxic effect. In addition, when a prolonged administration schedule is adopted, there is an inhibition of the repair of DNA breaks by cancer cells due to the prolonged topoisomerase II blockage. The efficacy and relative safety of prolonged administration of oral VP-16 have been demonstrated as monotherapy in the treatment of many cancers, including lung and breast cancers.

It has also been used successfully in combination with other antineoplastic agents, including cisplatin and carboplatin or additionally combined with ifosfamide, 5-fluorouracil, paclitaxel, or vincristine.

Based on the results of multiple clinical studies, small repeated doses of VP-16 appear to have a higher response rate than a single large dose. In addition, clinical responses to daily oral dosing of VP-16 are registered also in patients with...
tumors resistant to a short course (5 days) of VP-16 given intravenously.\(^\text{58}\) With regard to brain tumors, Relling and colleagues showed that a daily oral dose of at least 50 mg/m\(^2\) is required to achieve adequate cytotoxic concentrations into the cerebrospinal fluid compartment.\(^\text{59}\) With regard to the risk of secondary leukemia or myelodysplastic syndrome after treatment with VP-16, data available suggest a potential increased risk especially for patients receiving a high cumulative dose (i.e. \(>6\) g/m\(^2\)) or continuous administration (i.e. 21 consecutive days out of 28).\(^\text{60,61}\)

VP-16 treatment monotherapy has been adopted both for children and adult patients with brain tumors. Chamberlain and colleagues observed marginal toxicity and significant response rates of 50–63%, with responses lasting up to 8 months, when VP-16 was given orally over a prolonged period as salvage therapy in children and young adults suffering from relapsed or recurrent MB and low-grade gliomas.\(^\text{62–66}\) Similar results have been reported by other authors in a small series of patients with ependymomas and pediatric gliomas.\(^\text{57,67}\) In the Chamberlain studies, the authors emphasized that in children with recurrent nondisseminated intracranial ependymoma and who are resistant to surgery or other CT strategy, VP-16, administered orally and chronically, was well tolerated.

In a series of 12 patients, Chamberlain registered 2 PRs, 4 stable disease (SD), and 6 progression disease (PD) with a scheme of VP-16 orally administered at 50 mg/m\(^2\)/day for 21 consecutive days with a 14-day interval followed by an additional 21 consecutive days of oral VP-16.\(^\text{68}\) Of interest is a study by Pajtler and colleagues on the safety of the intraventricular VP-16 administration in patients with refractory or recurrent malignant brain tumors.\(^\text{69}\) Objective responses were reported in recurrent MB with schedules of oral VP-16 50–60 mg/m\(^2\)/day for 21 days as well as 50 mg/m\(^2\)/day for 10 days. Ashley and colleagues demonstrated the efficacy of the same schedule in 6 out of 7 patients with recurrent MB67 all previously treated with intravenous VP-16. Also, Needle and colleagues obtained a PR in 3 of 4 patients with primitive neuro-ectodermal tumor (PNET)/MB.\(^\text{38}\) Efficacy has also been reported by Schiavetti and colleagues adopting a 10-day schedule oral VP-16 in two children with MB (a CR and a PR, respectively).\(^\text{70}\) For all these schedules, the VP-16 orally administered was well tolerated and the acute toxicity mild. Perez-Somarriba and colleagues also demonstrated the success of treatment with etoposide in some cases of relapsed MB.\(^\text{39}\) In their phase II trial in children with newly diagnosed high-risk MB, Esbenshade and colleagues obtained an improvement, compared with the standard treatment, of the PFS and OS for these patients adopting an intensive protocol including oral VP-16. Patients were stratified into two groups based on the VP-16 dosage: 50 versus 35 mg/m\(^2\)/day during RT. Both groups then received, as adjuvant CT post-RT, cycles of cisplatin/oral etoposide and cyclophosphamide/vincristine. These results underline the need for evaluation of this treatment in larger trials to obtain more data about its toxicity before it can be adopted as standard therapy.\(^\text{71}\)

**Temozolomide**

TMZ is an alkylating antineoplastic drug that has shown promising activity in patients with malignant gliomas.\(^\text{72–76}\) TMZ belongs to the second-generation of imidazotetrazine prodrugs: their degradation at physiologic pH determines the formation of the cytotoxic monomethyl 5-triazeno imidazole carboxamide (MTIC). MTIC performs its antitumoral activity by adding methyl residues to the N\(^7\)-methylguanine, N\(^3\)-methyladenine, and O\(^6\)-methylguanine nucleotides in the DNA molecule.\(^\text{72,73}\)

Following oral administration, the bioavailability is approximately 100% within 2 hours after its administration due to the rapid adsorption. TMZ is able to cross the blood–brain barrier so it was of interest for the treatment of CNS neoplasms. Its first use was in early clinical trials enrolling patients with malignant high-grade gliomas. The activity of TMZ was established by two pivotal studies in adult patients with recurrent anaplastic astrocytoma and glioblastoma; notably, the treatment was well tolerated with minimal side effects.\(^\text{72,73}\) TMZ has demonstrated efficacy when utilized with lomustine as adjuvant therapy after TMZ plus RT for the therapy of pediatric high-grade gliomas.\(^\text{77}\) The antitumor activity of TMZ appeared to be schedule dependent, and TMZ achieved higher response rates when the total dose was administered over 5 days.

Estlin and colleagues in their phase I trial enrolling children with high-grade astrocytomas defined the TMZ maximum-tolerated dose: 200 mg/m\(^2\) once daily for 5 consecutive days was the recommended dose for phase II studies in children who have not previously treated with cranio-spinal irradiation or nitrosurea-based CT.\(^\text{78}\) Adopting that recommended dose for the following phase II clinical trial in pediatric patients with relapsed or progressive high-grade astrocytomas, the United Kingdom Children’s Cancer Study Group (UKCCSG)/SFOP group reported a response rate of 12 and 6% for supratentorial high-grade and brainstem gliomas, respectively.\(^\text{79}\) Vershuur and colleagues studied 20 children with recurrent high-grade gliomas as a single institution experience at the Institut Gustave Roussy. They reported an overall response rate of 20% (1 very good partial response (VGPR) and 3 PR) and a median survival up to 10 months.\(^\text{80}\) Eleven patients reported an improvement of their clinical status, and almost 50% of them could decrease or stop corticosteroids. In an Italian phase II study
enrolling 24 children with recurrent or relapsed high-grade glioma (including 7 brain stem tumors), TMZ showed only a marginal activity. No CR or PR was observed, and SD was the best response. Steroid withdrawal was not possible in any patient, and a reduction of steroid dosage was obtained in three patients.81

Rizzo and colleagues demonstrated that RT plus TMZ did not lead to a better disease-free survival than RT alone, though OS was greater than in other studies, demonstrating that RT plus TMZ may affect survival.82

Chiang and colleagues evaluated the efficacy of TMZ and RT in patients with diffuse brainstem gliomas. Patients were divided into two groups: the first one received RT alone followed by TMZ, and the second RT and concomitant TMZ 75 mg/m²/day followed by further cycles with TMZ. In both groups, there was no CR to RT, and all patients experienced disease progression. Therefore, TMZ in addition to RT did not produce better results than RT alone.83

In an American phase I study of TMZ in pediatric tumors, three objective responses after two cycles were observed (1 supratentorial PNET, 1 MB, and 1 malignant glioma).84

In an Italian cooperative study on children with relapsed and/or refractory MB, TMZ showed a significant activity with a response rate (CR + PR) of 48.6% (personal data). With regard to toxicity, grade 3–4 thrombocytopenia and grade 3–4 neutropenia were registered in 32 and 18% of the total 28 cycles, respectively.85

Unfortunately, the hypermethylation status of the MGMT gene promoter region appears to affect the efficacy of TMZ in adult patients with glioblastoma: the MGMT gene promoter methylation has been reported as the strongest predictive factor of survival in patients with glioblastoma. The potential impact of this evidence for childhood high-grade gliomas is not yet completely clear.3

Ridola and colleagues evaluated the influence of MGMT status on treatment efficacy. They evaluated the adoption of a metronomic administration: that is, 21 days dosing TMZ 70 mg/m²/day with a 7 days’ break schedule. The administration of CT at a lower dosage and longer duration obtained a complete or partial inhibition of the enzyme MGMT in contrast to the 5-days administration schedule. In addition, a higher cumulative dose was achieved with metronomic CT without increasing the toxicity profile, mainly represented by lymphocytopenia.86

Cefalo and colleagues studied the clinical efficacy of TMZ in children with high-grade astrocytomas and relapsed MB.87 For the 40 patients treated, the results were: 6 CR, 11 PR, 10 SD, and 13 PD. Responses to TMZ were registered at a dosage of 120 mg/m²/day with tolerable toxicity. The disease-free survival and OS at 6 and 12 months were 30 and 7.5% and 42.5 and 17.5%, respectively. By comparison, in patients who obtained an objective response, the disease-free survival and OS at 6 and 12 months were 70.6 and 17.5% and 94 and 41.2%, respectively. In addition, it was noted that 3-times-a-day administration, unlike single-dose administration, was associated with longer-lasting inhibition of the MGMT enzyme.87

In the case studies reported by Wang and colleagues on eight patients with recurrent embryonal tumors, TMZ 150–200 mg/m²/day was administered for five consecutive days every 28 days. All children had received prior surgery, craniospinal RT and CT. The use of TMZ was of clinical benefit in 4 out of 8 patients, and the disease-free progression was 15.7 months.88 Finally, Gurrurangan and colleagues evaluated the TMZ activity in progressive low-grade gliomas.89 The drug was administered at a dosage of 200 mg/m²/day for five consecutive days every 28 days. Disease-free survival at 2 and 4 years was 51 and 17%, respectively. OS at 2 and 4 years was 97 and 71%, respectively. These results underline the importance of considering TMZ as second-line treatment in children with nonresponsive low-grade glioma.

### Etoposide and temozolomide combination

The oral VP-16–TMZ combination was designed to identify whether there is potentially an increase in the therapeutic index by TMZ and VP-16 in treating children with recurrent malignant brain tumors.

Recently, the activity of TMZ combined with oral VP-16 for children and young adults with recurrent malignant astrocytomas has been reported.90 In the analysis, 11 patients received different combinations of TMZ (150–210 mg/m²/day for 5 days) and oral VP-16 (50 mg/m²/day for 4–12 days). All patients were previously treated with RT, and seven patients received CT. In total, 1 CR and 6 PR were observed.

Ruggiero and colleagues have evaluated CT with VP-16 and TMZ in patients with recurrent or progressive MB/PNET.91 The objective responses registered for both drugs given simultaneously were better than the use of the two drugs separately. Among the 14 patients enrolled, 1 CR and 1 PR were noted. In another study, Ruggiero and colleagues analyzed the response rate to oral VP-16-TMZ in children with malignant glial tumors. The best response was the stability of the disease; neither CR nor PR was found.92

In conclusion, an appealing practice may be derived from the combination of a DNA alkylating agent with an inhibitor of the topoisomerase enzyme taking into account that the topoisomerases are essential to activate the DNA repair mechanisms following DNA alkylation. TMZ might enhance the recruitment of the topoisomerases by methylating the O6 position of guanine: the final result is a theoretical enhancement of the topoisomerase inhibitor activity.93

### Conclusions

The reported data suggest a potential activity of oral VP-16 and TMZ alone or in combination. Taking into account their favorable pharmacokinetic profile, oral administration, marginal toxicity, and the responses registered in different malignant brain tumors, further clinical trials are needed to explore and confirm their promising activity in relapsed brain neoplasms.
Contributions: All authors contributed equally to the preparation of this review. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2020/05/dic.2020-3-1-COI.pdf

Acknowledgements: This work was technically supported by ‘Sara un angelo con la bandana Onlus.’ We thank them for their dedicated patient care.

Funding declaration: There was no funding associated with the preparation of this article.

Copyright: Copyright © 2020 Ruggiero A, Ariano A, Triarico S, Capozza MA, Romano A, Maurizi P, Mastrangelo S, Attinà G. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2020 Ruggiero A, Ariano A, Triarico S, Capozza MA, Romano A, Maurizi P, Mastrangelo S, Attinà G. https://doi.org/10.7573/dic.2020-3-1. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/temozolomide-and-oral-etoposide-in-children-with-recurrent-malignant-brain-tumors

Correspondence: Antonio Ruggiero (ORCID 0000-0002-6052-3511), Paediatric Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168 Rome, Italy. antonio.ruggiero@unicatt.it

Provenance: submitted; externally peer reviewed.

Submitted: 9 March 2020; Peer review comments to author: 28 April 2020; Revised manuscript received: 1 May 2020; Accepted: 8 May 2020; Publication date: 2 June 2020.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 SPT. BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editor-in-Chief gordon.mallarkey@bioexcelpublishing.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

References

1. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803–820. https://doi.org/10.1007/s00401-016-1545-1

2. Broniscer A, Gajjar A. Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist. 2004;9(2):197–206. https://doi.org/10.1634/theoncologist.9-2-197

3. Jones C, Karajannis MA, Jones DTW, et al. Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro Oncol. 2017;19(2):153–161. https://doi.org/10.1093/neo/jow010

4. Braunstein S, Raleigh D, Ranjit Bindra B, et al. Pediatric high-grade glioma: current molecular landscape and therapeutic approaches. J Neurooncol. 2017;134(3):541–549. https://doi.org/10.1007/s11060-017-2393-0

5. Wells EM, Packer RJ. Pediatric brain tumors. Continuum (Minneap Minn). 2015;21(2 Neuro-oncology):373–396. https://doi.org/10.1212/CON.0000464176.96311.d1

6. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17(8):2572–2578. https://doi.org/10.1200/JCO.1999.17.8.2572

7. Huncharek M, Wheeler L, McGarry R, Geschwind JF. Chemotherapy response rates in recurrent/progressive pediatric glioma; results of a systematic review. Anticancer Res. 1999;19(4C):3569–3574.

8. Hodgson DC, Goumnerova LC, Loeffler JS, et al. Radiosurgery in the management of pediatric brain tumors. Int J Radiat Oncol Biol Phys. 2001;50(4):929–935. https://doi.org/10.1016/S0360-3016(01)01518-8

9. Murphy ES, Chao ST, Angelov L, et al. Radiosurgery for pediatric brain tumors. Pediatr Blood Cancer. 2016;63(3):398–405. https://doi.org/10.1002/pbc.25831

10. Fiorillo A, Maggi G, Greco N, et al. Second-line chemotherapy with the association of liposomal daunorubicin, carboplatin and etoposide in children with recurrent malignant brain tumors. J Neurooncol. 2004;66(1–2):179–185. https://doi.org/10.1023/b:neon.000013471.53015.52

11. Mason WP, Goldman S, Yates AJ, et al. Survival following intensive chemotherapy with bone marrow reconstitution for children with recurrent intracranial ependymoma—a report of the Children’s Cancer Group. J Neurooncol. 1998;37(2):135–143. https://doi.org/10.1023/a:1005980206723
12. Bouffet E, Philip T, Negrier C, et al. Phase I study of interleukin-6 in children with solid tumours in relapse. Eur J Cancer. 1997;33(10):1620–1626. https://doi.org/10.1016/S0959-8049(97)00181-0

13. McCowage GB, Friedman HS, Moghrabi A, et al. Activity of high-dose cyclophosphamide in the treatment of childhood malignant gliomas. Med Pediatr Oncol. 1998;30(2):75–80. https://doi.org/10.1002/(sici)1096-911x(199802)30:2<75::aid-mpo1>3.0.co;2-x

14. Friedman H, Krischer JP, Burger P, et al. Treatment of children with progressive or recurrent brain tumors with carboplatin or iprsiplatin: a Pediatric Oncology Group randomized phase II study. J Clin Oncol. 1992;10(2):249–256. https://doi.org/10.1200/JCO.1992.10.2.249

15. Perez-Somarriva M, Andión M, López-Pino MA, et al. Old drugs still work! Oral etoposide in a relapsed medulloblastoma. Childs Nerv Syst. 2019;35(5):865–869. https://doi.org/10.1007/s00381-019-04072-9

16. Millard NE, De Braganca KC. Medulloblastoma. J Child Neurol. 2016;31(12):1341–1353. https://doi.org/10.1177/0883073815600866

17. Allen JC, Henson L. High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children. J Neurosurg. 1981;55(5):749–756. https://doi.org/10.3171/jns.1981.55.5.0749

18. Heideman RL, Packer RJ, Reaman GH, et al. A phase II evaluation of thiopeta in pediatric central nervous system malignancies. Cancer. 1993;72(1):271–275. https://doi.org/10.1002/1097-0142(19930701)72:1<271::aid-cncr2820720147>3.0.co;2-k

19. Gaynon PS, Ettinger LJ, Baum ES, et al. Carboplatin in childhood brain tumors. A Children’s Cancer Study Group Phase II trial. Cancer. 1990;66(12):2465–2469. https://doi.org/10.1002/1097-0142(19901215)66:12<2465::aid-cncr2820661204>3.0.co;2-n

20. Ruggiero A, De Rosa G, Rizzo D, et al. Myocardial performance index and biochemical markers for early detection of doxorubicin-induced cardiotoxicity in children with acute lymphoblastic leukaemia. Int J Clin Oncol. 2013;18(5):927–933. https://doi.org/10.1007/s10147-012-0458-9

21. Ruggiero A, Maurizi P, Larocca LM, Arlotta A, Riccardi R. Childhood CD4+/CD56+ hematodermic neoplasm: case report and review of the literature. Haematologica. 2006;91(S12):ECR48.

22. Chiaretti A, Ruggiero A, Barbi E, et al. Propofol/fentanyl and propofol/ketamine procedural sedation in children with acute lymphoblastic leukaemia: safety, efficacy and pain correlation with pain neuromediator expression. Eur J Cancer Care. (Engl) 2010;19(2):212–220. https://doi.org/10.1111/j.1365-2354.2008.01006.x

23. Chiaretti A, Ruggiero A, Barbi E, et al. Comparison of propofol versus propofol-ketamine combination in pediatric oncologic procedures performed by non-anesthesiologists. Pediatr Blood Cancer. 2011;57(7):1163–1167. https://doi.org/10.1002/pbc.23170

24. Packer RJ, Sutton LN, Elterman R, et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg. 1994;81(5):690–698. https://doi.org/10.3171/jns.1994.81.5.0690

25. Bailey CC, Gnekow A, Wellek S, et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Med Pediatr Oncol. 1995;25(3):166–178. https://doi.org/10.1002/1096-911x(199525)25<166::aid-mpo1>3.0.co;2-x

26. Evans AE, Jenkin RD, Sposto R, et al. The treatment of medulloblastoma. Results of a prospective randomised trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg. 1990;72(4):572–582. https://doi.org/10.3171/jns.1990.72.4.0572

27. Balter-Seri J, Mor C, Shuper A, et al. Cure of recurrent medulloblastoma: the contribution of surgical resection at relapse. Cancer. 1997;79(6):1241–1247. https://doi.org/10.1002/1097-0142(19970315)79:6<1241::aid-cncr2820730303>3.0.co;2-x

28. Torres CF, Rebsamen S, Silber JH, et al. Surveillance scanning of children with medulloblastoma. N Engl J Med. 1994;330(13):892–895. https://doi.org/10.1056/NEJM199403153301303

29. Belza MG, Donaldson SS, Steinberg GK, et al. Medulloblastoma: freedom from relapse longer than 8 years – a therapeutic cure? J Neurosurg. 1991;75(4):575–582. https://doi.org/10.3171/jns.1991.75.4.0575

30. Bouffet E, Doz F, Demaillé MC, et al. Improving survival in recurrent medulloblastoma: earlier detection, better treatment or still an impasse? J Clin Cancer. 1998;77(8):1321–1326. https://doi.org/10.1038/bjc.1998.220

31. Sonnichsen DS, Ribeiro RC, Luo X, Mathew P, Relling MV. Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors. Clin Pharmacol Ther. 1995;58(1):99–107. https://doi.org/10.1002/1097-9236(199507)58:1<99::aid-clpt7>3.0.co;2-7

32. Miller AA, Herndon JE 2nd, Hollis DR, et al. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. J Clin Oncol. 1995;13(8):1871–1879. https://doi.org/10.1200/JCO.1995.13.8.1871

33. Thompson DS, Hainsworth JD, Hande KR, et al. Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase II study. J Clin Oncol. 1993;11(7):1322–1328. https://doi.org/10.1200/JCO.1993.11.7.1322

34. Thompson DS, Hainsworth JD, Hande KR, et al. Prolonged administration of low-dose infusional etoposide in patients with advanced malignancies. A phase II study. Cancer. 1994;73(11):2824–2831. https://doi.org/10.1002/1097-0142(19940601)73:11<2824::aid-cncr2820731127>3.0.co;2-t
35. Minami H, Shimokata K, Saka H, et al. Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer. *J Clin Oncol*. 1993;11(8):1602–1608. https://doi.org/10.1200/JCO.1993.11.8.1602

36. Joel SP, Shah R, Clark PI, Slevin ML. Predicting etoposide toxicity: relationship to organ function and protein binding. *J Clin Oncol*. 1996;14(1):257–267. https://doi.org/10.1200/JCO.1996.14.1.257

37. Kiya K, Uozumi T, Ogasawara H, et al. Penetration of etoposide into human malignant brain tumors after intravenous and oral administration. *Cancer Chemother Pharmacol*. 1992;29(5):339–342. https://doi.org/10.1007/bf00686001

38. Slevin ML, Clark PI, Joel SP, et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. *J Clin Oncol*. 1989;7(9):1333–1340. https://doi.org/10.1200/JCO.1989.7.9.1333

39. Hande KR, Krozely MG, Greco FA, et al. Bioavailability of low-dose oral etoposide. *J Clin Oncol*. 1993;11(2):374–377. https://doi.org/10.1200/JCO.1993.11.2.374

40. De Jong RS, Mulder NH, Dijkstra D, de Vries EG. Review of current clinical experience with prolonged (oral) etoposide in cancer treatment. *Anticancer Res*. 1995;15(SB):2319–2330.

41. Toffoli G, Corona G, Basso B, Boiocchi M. Pharmacokinetic optimisation of treatment with oral etoposide. *Clin Pharmacokinet*. 2004;43(7):441–466. https://doi.org/10.2165/00003088-200443070-00002

42. Johnson DH, Hainsworth JD, Hande KR, Greco FA. Current status of etoposide in the management of small cell lung cancer. *Cancer*. 1991;67(1 Suppl):231–244.

43. Waits TM, Johnson DH, Hainsworth JD, et al. Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial. *J Clin Oncol*. 1992;10(2):292–296. https://doi.org/10.1200/JCO.1992.10.2.292

44. DeVore R, Hainsworth J, Greco FA, et al. Chronic oral etoposide in the treatment of lung cancer. *Semin Oncol*. 1992;19(6 Suppl 14):28–35.

45. Atienza DM, Vogel CL, Trock B, Swain SM. Phase II study of oral etoposide for patients with advanced breast cancer. *Cancer*. 1995;76(12):2485–2490. https://doi.org/10.1002/1097-0142(19951215)76:12<2485::aid-cnrc2820761212>3.0.co;2-j

46. Shaffer DW, Smith LS, Burris HA, et al. A randomized phase II trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies. *Cancer Res*. 1993;53(24):5929–5933.

47. Hainsworth JD, Levitan N, Wampler GL, et al. Phase II randomized study of cisplatin plus etoposide phosphate or etoposide in the treatment of small-cell lung cancer. *J Clin Oncol*. 1995;13(6):1436–1442. https://doi.org/10.1200/JCO.1995.13.6.1436

48. Murphy PB, Hainsworth JD, Greco FA, et al. A phase II trial of cisplatin and prolonged administration of oral etoposide in extensive-stage small cell lung cancer. *Cancer*. 1992;69(2):370–375. https://doi.org/10.1002/1097-0142(19920215)69:2<370::aid-cnrc282069217>3.0.co;2-e

49. Loeher PJ Sr, Ansari R, Gonin R, et al. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. *J Clin Oncol*. 1995;13(10):2594–2599. https://doi.org/10.1200/JCO.1995.13.10.2594

50. Lynch TJ Jr, Kass F, Kalish LA, et al. Cisplatin, 5-fluorouracil, and etoposide for advanced non-small cell lung cancer. *Cancer*. 1993;71(10):2953–2957. https://doi.org/10.1002/1097-0142(19930515)71:10<2953::aid-cnrc2820711011>3.0.co;2-j

51. Hainsworth JD, Stroup SL, Greco FA. Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma. *Cancer*. 1996;77(12):2458–2463. https://doi.org/10.1002/(SICI)1097-0142(19960615)77:12<2458::AID-CNCR7>3.0.CO;2-I

52. Gatzemeier U, Pawel JW, Laumen R, et al. Etoposide/vincristine-based chemotherapy with or without carboplatin in extensive-stage small cell lung cancer: a prospective randomized phase III trial. *Semin Oncol*. 1994;21(3 Suppl 6):31–35.

53. Ruggiero A, Rizzo D, Mastrangelo S, et al. Interactions between antiepileptic and chemotherapeutic drugs in children with brain tumors: is it time to change treatment? *Pediatr Blood Cancer*. 2010;54(2):193–198. https://doi.org/10.1002/pbc.22276

54. Chiaretti A, Aloé L, Antonelli A, et al. Neurotrophic factor expression in childhood low-grade astrocytomas and ependymomas. *Childs Nerv Syst*. 2004;20:412–419. https://doi.org/10.1007/s00381-004-0959-6

55. Lazzareschi I, Ruggiero A, Riccardi R, et al. Hypersensitivity reactions to carboplatin in children. *J Neurooncol*. 2002;58:33–37. https://doi.org/10.1023/a:1015585300090

56. Falsini B, Chiaretti A, Barone G, et al. Nerve growth factor improves visual loss in childhood optic gliomas: a randomized, double-blind, phase II clinical trial. *Brain*. 2016;139(Pt 2):404–414. https://doi.org/10.1093/brain/awv366

57. Falsini B, Chiaretti A, Barone G, et al. Topical nerve growth factor as a visual rescue strategy in pediatric optic gliomas: a pilot study including electrophysiology. *Neurorehabil Neural Repair*. 2011;25(6):512–520. https://doi.org/10.1177/154596310397201

58. Needle MN, Molloy PT, Geyer JR, et al. Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors. *Med Pediatr Oncol*. 1997;29(1):28–32. https://doi.org/10.1002/(sici)1096-911x(19970729)29:1<28::aid-mpo5>3.0.co;2-u

59. Relling MV, Mahmoud HH, Pui CH, et al. Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia. *J Clin Oncol*. 1996;14(2):399–404. https://doi.org/10.1200/JCO.1996.14.2.399

60. Smith MA, Rubinstein L, Anderson JR, et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. *J Clin Oncol*. 1999;17(2):569–577. https://doi.org/10.1200/JCO.1999.17.2.569
61. Le Deley MC, Leblanc T, Shamsaldin A, et al; Société Française d’Oncologie Pédiatrique. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Française d’Oncologie Pédiatrique. *J Clin Oncol.* 2003;21(6):1074–1081. https://doi.org/10.1200/JCO.2003.04.100

62. Chamberlain MC. Recurrent brainstem gliomas treated with oral VP-16. *J Neurooncol.* 1993;15(2):133–139. https://doi.org/10.1007/bf01053934

63. Chamberlain MC, Grafe MR. Recurrent chiasmatic-hypothalamic glioma treated with oral etoposide. *J Clin Oncol.* 1995;13(8):2072–2076. https://doi.org/10.1200/JCO.1995.13.8.2072

64. Chamberlain MC. Recurrent cerebellar gliomas: salvage therapy with oral etoposide. *J Child Neurol.* 1997;12(3):200–204. https://doi.org/10.1177/088303319701200309

65. Chamberlain MC. Recurrent supratentorial malignant gliomas in children. Long-term salvage therapy with oral etoposide. *Arch Neurol.* 1997;54(5):554–558. https://doi.org/10.1001/archneur.1997.00550170036012

66. Chamberlain MC, Kormanik PA. Chronic oral VP-16 for recurrent medulloblastoma. *Pediatr Neurol.* 1997;17(3):230–234. https://doi.org/10.1016/S0887-8994(97)00098-2

67. Ashley DM, Meier L, Kerby T, et al. Response of recurrent medulloblastoma to low-dose oral etoposide. *J Clin Oncol.* 2001;19(2):117–121. https://doi.org/10.1001/jco.2001.053000400000249

68. Pajtler KW, Tippelt S, Siegler N, et al. Intraventricular etoposide safety and toxicity profile in children and young adults with refractory or recurrent malignant brain tumors. *J Neurooncol.* 2016;128(3):463–471. https://doi.org/10.1007/s11060-016-2133-x

69. Schiavetti A, Varraso G, Maurizi P, et al. Ten-day schedule oral etoposide therapy in advanced childhood malignancies. *J Pediatr Hematol Oncol.* 2000;22(2):119–124. https://doi.org/10.1097/00043426-200003000-00008

70. Esbenshade AJ, Kocak M, Hershon L, et al. A Phase II feasibility study of oral etoposide given concurrently with radiotherapy followed by dose intensive adjuvant chemotherapy for children with newly diagnosed high risk medulloblastoma (protocol POG 9631): A report from the Children’s Oncology Group. *Pediatr Blood Cancer.* 2017;64(6). https://doi.org/10.1002/pbc.26373

71. Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. *Br J Cancer.* 2000;83(5):588–593. https://doi.org/10.1054/bjoc.2000.1316

72. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. *J Clin Oncol.* 1999;17(9):2762–2771. https://doi.org/10.1200/JCO.1999.17.9.2762

73. Trisciuzzi MT, Riccardi R, Piccardi M, et al. A fast visual evoked potential method for functional assessment and follow-up of childhood optic gliomas. *Clin Neurophysiol.* 2004;115:217–226. https://doi.org/10.1016/S1388-2457(03)00282-7

74. Falsini B, Riccardi L, Lazzareschi I, et al. Longitudinal assessment of childhood optic gliomas: relationship between flicker visual evoked potentials and magnetic resonance imaging findings. *J Neurooncol.* 2008;88:87–96. https://doi.org/10.1007/s11060-008-9537-1

75. luvone L, Peruzzi L, Colosimo C, et al. Pretreatment neuropsychological deficits in children with brain tumors. *Neuro Oncol.* 2011;13(5):517–524. https://doi.org/10.1093/neuonc/nor013

76. Jakaci RI, Cohen KJ, Buxton A, et al. Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children’s Oncology Group ACNS0423. *Neuro Oncol.* 2016;18(10):1442–1450. https://doi.org/10.1093/neuonc/nox038

77. Estlin EJ, Lashford L, Ablett S, et al. Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children’s Cancer Study Group. *Br J Cancer.* 1998;78(5):652–661. https://doi.org/10.1038/bjc.1998.555

78. Lashford LS, Thiesse P, Jouvet A, et al. United Kingdom Children’s Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. Temozolomide in malignant gliomas of childhood: a United Kingdom Children’s Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. *J Clin Oncol.* 2002;20(24):4684–4691. https://doi.org/10.1200/JCO.2002.08.141

79. Verschuer AC, Grill J, Lelouch-Tubiana A, et al. Temozolomide in paediatric high-grade glioma: a key for combination therapy? *Br J Cancer.* 2004;91(3):425–429. https://doi.org/10.1038/sj.bjc.6601997

80. Ruggiero A, Ariano A, Tria neatly S, Capoza MA, et al. Drugs in Context 2020; 9: 2020-3-1. DOI: 10.7573/dic.2020-3-1

ISSN: 1740-4398
85. Riccardi A, Mazzarella G, Cefalo G, et al. Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients. *Cancer Chemother Pharmacol*. 2003;52(6):459–464. https://doi.org/10.1007/s00280-003-0677-x

86. Ridola V, Barone G, Lazzareschi I, et al. Feasibility study of 21-day-on/7-day-off temozolomide in children with brain tumors. *J Neurooncol*. 2011;103(1):147–153. https://doi.org/10.1007/s11060-010-0371-x

87. Cefalo G, Massimino M, Ruggiero A, et al. Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial. *Neuro Oncol*. 2014;16(5):748–753. https://doi.org/10.1093/neuonc/not320

88. Wang CH, Hsu TR, Wong TT, Chang KP. Efficacy of temozolomide for recurrent embryonal brain tumors in children. *Childs Nerv Syst*. 2009;25(5):535–541. https://doi.org/10.1007/s00381-008-0781-7

89. Gururangan S, Fisher MJ, Allen JC, et al. Temozolomide in children with progressive low-grade glioma. *Neuro Oncol*. 2007;9(2):161–168. https://doi.org/10.1016/j.neuonc.2006.030

90. Korones DN, Smith A, Foreman N, Bouffet E. Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas. *Pediatr Blood Cancer*. 2006;47(1):37–41. https://doi.org/10.1002/pbc.20510

91. Ruggiero A, Rizzo D, Attinà G, et al. Phase I study of temozolomide combined with oral etoposide in children with recurrent or progressive medulloblastoma. *Eur J Cancer*. 2010;46(16):2943–2949. https://doi.org/10.1016/j.ejca.2010.05.016

92. Ruggiero A, Rizzo D, Attinà G, et al. Phase I study of temozolomide combined with oral etoposide in children with malignant glial tumors. *J Neurooncol*. 2013;113(3):513–518. https://doi.org/10.1007/s11060-013-1145-z

93. Prados M. Temozolomide in combination with other cytotoxic agents. *Semin Oncol*. 2001;28(4 Suppl 13):24–33. https://doi.org/10.1016/S0093-7754(01)90068-5